Comparison in the efficacy of the two add on therapies with an anticholinergic agent versus a beta3-adrenoceptor agonist for patients with benign prostatic enlargement complicated by overactive bladder after alpha1-blocker administration, A randomized, prospective trial using a urodynamic study

INTERVENTION: The administration of fesoterodine The administration of mirabegron CONDITION: benign prostatic enlargement complicated by overactive bladder PRIMARY OUTCOME: the change of storage and voiding function between the two add on therapies after 12 weeks' treatment SECONDARY OUTCOME: the change of subjective symptoms regarding lower urinary tract symptoms between the two add on therapies after 12 weeks' treatment INCLUSION CRITERIA: 1) patinets who have taken alpha‐1 blocker for more than 12 weeks 2) total OAB symptom scores (OABSS) more than 2 and urinary urgency episodes more than 1 per week 3) outpatinets more than 50 years old